乳腺癌雌孕激素受体与C-erbB-2基因蛋白表达及相关分析研究  

Expression of C-erbB-2 gene and ER、PR and their interrelationship in breast cancer

作　　者：徐胜前[1] 张春辉[1] 尤其俋[1] 

机构地区：[1]南通大学附属医院普外科,南通226001

出　　处：《南通大学学报（医学版）》2005年第3期180-182,共3页Journal of Nantong University(Medical sciences)

摘　　要：目的:观察乳腺癌组织中雌孕激素受体与C-erbB-2基因蛋白表达,并探讨它们之间的相关性。方法:用免疫组化法(S-P法)测定62例术前未行化、放疗的原发性乳腺癌中C-erbB-2、雌激素受体、孕激素受体的表达情况,并作统计学分析。结果:(1)C-erbB-2、雌激素受体、孕激素受体的阳性率分别为67.8%(42/62)、45.2%(28/62)、48.4%(30/62);(2)雌激素受体、孕激素受体与临床病理参数无关,C-erbB-2仅与腋窝淋巴结转移呈明显正相关(P<0.05);(3)雌激素受体、孕激素受体均阳性患者C-erbB-2的阳性率明显低于二者均阴性表达患者(P<0.05);(4)C-erbB-2(+)且雌激素受体(-)患者与腋窝淋巴结转移呈明显正相关,差异有显著性(P<0.05)。结论:C-erbB-2与雌激素受体、孕激素受体同时表达存在明显负相关,C-erbB-2基因高表达或C-erbB-2(+)且雌激素受体(-)的患者易出现腋窝淋巴结转移,预后往往不佳。Objectives:To observe the protein expression of C-erbB-2,ER and PR in human breast cancer and to explore their interrelationship.Methods:The expression of C-erbB-2,ER and PR were detected in formalin-fixed、paraffin-embeded tissues from 62 breast cancer patients by immunohistochemistry.Results of detection were analyzed statistically.Results:(1)Positive rates of C-erbB-2,ER and PR expression were 67.8%(42/62)、45.2%(28/62)and 48.4%(30/62) respectively.(2)No relation could be established between expression of ER or PR and clinicopathological parameters,but the expression of C-erbB-2 had a positive correlation with axilla lymphatic metastasis significantly(P<0.05).(3)The positive rate of C-erbB-2 expression in both ER(+) and PR(+) breast cancer tissues was apparently lower than that in both ER(-) and PR(-) tissues(P<0.05).(4)The expression of both C-erbB-2(+) and ER(-) was related to axilla lymph node metastasis obviously,and there was significant difference(P<0.05).Conclusion:Expression of C-erbB-2 has a reverse correlation with the simultaneous expression of ER and PR. Axilla lymphatic metastasis can be found in patients with C-erbB-2(+) or with C-erbB-2(+) and ER(-),whose prognoses may be worse.

关 键 词：C-ERBB-2基因蛋白 雌孕激素受体 相关分析研究 腋窝淋巴结转移 表达及 雌激素受体 基因蛋白表达 原发性乳腺癌 临床病理参数 乳腺癌组织 免疫组化法 统计学分析 S-P法 表达情况 阴性表达 阳性患者 阳性率 正相关 相关性 

分 类 号：R737.9[医药卫生—肿瘤] R737.25[医药卫生—临床医学]